Bio-Rad Laboratories Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1994
Net Income	-637.32	-3,627.54	4,254	3,814	1,759	Upgrade
Other Operating Activities	1,012	3,822	-3,584.79	-3,229.26	-1,300.78	Upgrade
Operating Cash Flow	374.94	194.45	669.46	584.97	457.9	Upgrade
Operating Cash Flow Growth	92.83%	-70.95%	14.44%	27.75%	60.39%	Upgrade
Capital Expenditures	-156.47	-112.62	-133.69	-108.49	-98.4	Upgrade
Acquisitions	2.5	-99.39	-125.52	-84.42	-79.39	Upgrade
Change in Investments	174.18	-994.21	-538.17	119.6	-39.92	Upgrade
Other Investing Activities	-	-1.38	-	3.41	8.82	Upgrade
Investing Cash Flow	20.21	-1,207.59	-797.38	-69.89	-208.89	Upgrade
Share Issuance / Repurchase	-410.24	-198.12	-29.37	-79.81	-11.06	Upgrade
Debt Issued / Paid	-0.47	1,186	-3.02	-426.94	-1.13	Upgrade
Other Financing Activities	-14.94	-14.02	-23.04	-16.3	-10.57	Upgrade
Financing Cash Flow	-425.65	973.58	-55.43	-523.04	-22.76	Upgrade
Exchange Rate Effect	0.32	2.98	-12.64	12.43	2.24	Upgrade
Net Cash Flow	-30.18	-36.59	-195.98	4.46	228.49	Upgrade
Free Cash Flow	218.47	81.83	535.77	476.48	359.49	Upgrade
Free Cash Flow Growth	167.00%	-84.73%	12.44%	32.54%	124.71%	Upgrade
Free Cash Flow Margin	8.18%	2.92%	18.33%	18.72%	15.55%	Upgrade
Free Cash Flow Per Share	7.48	2.75	17.96	16.01	12.05	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).